An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Researchers and drug developers are talking about a new kind of weight-loss medicine that targets three hormone receptors at once. The idea is that hitting three different signals in the body may lead to bigger and longer-lasting weight loss than drugs that only target one. The news mainly comes from early clinical trials and presentations by the companies making these drugs, showing promising weight loss numbers compared with existing single-target medicines. The drug class people are excited about are called "triple agonists." That sounds fancy, but it just means a single medicine acts like three different natural hormones at once. One example is retatrutide, which mimics versions of GLP-1, GIP and glucagon — three gut and metabolic hormones that help control appetite, blood sugar, and how the body uses energy. For comparison, existing popular drugs like semaglutide (Ozempic, Wegovy) mainly mimic GLP-1 only. So triple agonists are designed to combine the appetite-suppressing and blood-sugar effects of GLP-1 with complementary effects from the other two hormones. What the research shows so far is early but encouraging: small to mid-size clinical trials report larger average weight loss than current GLP-1 drugs. Many of the results come from company-run Phase 2 trials — these involve a few dozen to a few hundred participants over several months. Reported weight loss numbers have been substantially higher in some reports, but the results are not yet from large, long-term Phase 3 trials that regulators require for approval. So the effect appears real in controlled trials, but the full picture on how much better and how durable the benefit will be is still incomplete. This matters because obesity and related conditions like diabetes affect millions, and more effective medicines could help people lose significant weight and improve health without surgery. If triple agonists deliver substantially greater weight loss safely, they could change treatment options for people struggling with weight, or for doctors who need stronger tools. People with type 2 diabetes, severe obesity, or those who haven’t responded well to single-hormone drugs might be especially interested. There are important caveats and risks. Most data so far are early and from relatively small, company-sponsored studies; results can look better in early trials than in broader use. Side effects typical of these hormone drugs include nausea, vomiting, diarrhea, and sometimes more serious issues like gallbladder problems or pancreatitis — combining three hormonal actions may change the side-effect profile in unpredictable ways. Long-term safety and whether weight stays off after stopping the drug are unknown. These drugs aren’t approved for general use yet; they’ll need larger, longer trials and regulatory review. People who are pregnant, breastfeeding, or have certain medical conditions should avoid these medicines until more is known. Bottom line: Triple agonists like retatrutide are a promising next step beyond single-hormone weight drugs, but current evidence is early and more testing is needed to be sure they’re safer and more effective in the long run.
Source: r/Semaglutide